Cargando…
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
BACKGROUND: Rolapitant, a long-acting neurokinin (NK)(1) receptor antagonist (RA), has demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in patients administered moderately or highly emetogenic chemotherapy. Unlike other NK(1) RAs, rolapitant does not inhibit or induce...
Autores principales: | Barbour, S., Smit, T., Wang, X., Powers, D., Arora, S., Kansra, V., Aapro, M., Herrstedt, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452074/ https://www.ncbi.nlm.nih.gov/pubmed/28327932 http://dx.doi.org/10.1093/annonc/mdx073 |
Ejemplares similares
-
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
por: Rapoport, Bernardo Leon, et al.
Publicado: (2017) -
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018) -
Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016) -
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
por: Chasen, Martin, et al.
Publicado: (2016) -
Morphological and Skeletal Abnormalities Induced by Rolapitant: An Antiemetic Agent
por: Solanki, Sohel, et al.
Publicado: (2022)